目前，在博鳌乐城国际医疗旅游先行区特许医疗政策支持下，用于改善脊髓小脑变性病人的共济失调的药物他替瑞林在海南博鳌乐城可以申请使用，为国内众多脊髓小脑变性病人的治疗提供了新的选择。

Biohaven said its experimental treatment for a rare neurological condition showed "a robust and clinically meaningful" ...

Genetic analysis beyond the causative variants, and independent of the core clinical symptoms (pyramidal signs versus ataxia), might offer a more pertinent way to approach phenotypic variability.

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

每年的9月25日是国际共济失调日，旨在提高公众对共济失调（Ataxia）的认识和了解。因基因突变产生的遗传性神经系统退行性疾病会引发患者出现共济失调，从而在日常生活中出现平衡功能障碍、无法准确控制肢体、说话和视物也会出现问题。患者发病年龄从儿童到成年 ...

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...

Bill Nye, who has helped make science a part of pop culture for a generation of adults and children, is now using his ...

(RTTNews) - Biohaven Ltd. (BHVN) Monday said its pivotal study of troriluzole in Spinocerebellar Ataxia (SCA) met its primary goal. In the pre-market trade, the company's shares were rising about ...

Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of ...